JP2016020378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016020378A5 JP2016020378A5 JP2015197633A JP2015197633A JP2016020378A5 JP 2016020378 A5 JP2016020378 A5 JP 2016020378A5 JP 2015197633 A JP2015197633 A JP 2015197633A JP 2015197633 A JP2015197633 A JP 2015197633A JP 2016020378 A5 JP2016020378 A5 JP 2016020378A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- norovirus
- group
- gene group
- vlp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 241001263478 Norovirus Species 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 229920001661 Chitosan Polymers 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 3
- 230000003232 mucoadhesive effect Effects 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 108090000565 Capsid Proteins Proteins 0.000 claims 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- -1 unurine Polymers 0.000 claims 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 239000004382 Amylase Substances 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002567 Chondroitin Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84791206P | 2006-09-29 | 2006-09-29 | |
| US60/847,912 | 2006-09-29 | ||
| US97339207P | 2007-09-18 | 2007-09-18 | |
| US60/973,392 | 2007-09-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013131559A Division JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016020378A JP2016020378A (ja) | 2016-02-04 |
| JP2016020378A5 true JP2016020378A5 (cg-RX-API-DMAC10.html) | 2016-08-04 |
| JP6134364B2 JP6134364B2 (ja) | 2017-05-24 |
Family
ID=39268804
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530639A Active JP5476544B2 (ja) | 2006-09-29 | 2007-09-28 | ノロウイルスワクチン製剤 |
| JP2013131559A Active JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
| JP2015197633A Active JP6134364B2 (ja) | 2006-09-29 | 2015-10-05 | ノロウイルスワクチン製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530639A Active JP5476544B2 (ja) | 2006-09-29 | 2007-09-28 | ノロウイルスワクチン製剤 |
| JP2013131559A Active JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
Country Status (16)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2601969B1 (en) | 2006-09-29 | 2016-03-30 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| CA2683977C (en) * | 2007-03-14 | 2017-04-25 | Ligocyte Pharmaceuticals, Inc. | A method of norovirus virus-like particle purification comprising ion exchange chromatography |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| CN104740624B (zh) | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| JP5852883B2 (ja) * | 2008-08-08 | 2016-02-03 | タケダ ワクチン，インコーポレイテッド | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| WO2010111586A2 (en) * | 2009-03-27 | 2010-09-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Mucosal immunization |
| US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| WO2011079260A2 (en) * | 2009-12-23 | 2011-06-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
| JP2013517773A (ja) * | 2010-01-21 | 2013-05-20 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
| AU2012244077B2 (en) * | 2010-04-15 | 2015-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Methods and compositions for intranasal delivery |
| EP2689785B1 (en) * | 2010-04-15 | 2021-05-19 | Shin Nippon Biomedical Laboratories, Ltd. | Method for generating dry vaccine powder formulation for inranasal delivery |
| PH12014500093A1 (en) | 2011-07-11 | 2014-03-17 | Takeda Vaccines Inc | Parenteral norovirus vaccine formulations |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| US20140017257A1 (en) * | 2012-07-11 | 2014-01-16 | Xi Jiang | IgY From Norovirus P Particles And Their Derivatives |
| ES2677723T3 (es) * | 2012-12-28 | 2018-08-06 | Cellestis Limited | Un ensayo de la respuesta inmunológica mediada por células |
| EP2970395A4 (en) * | 2013-03-15 | 2017-03-29 | The University of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| US9975923B2 (en) | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| JP2015017065A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ノロウイルスのウイルス様粒子を含む医薬組成物 |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| CN105358178B (zh) | 2013-07-17 | 2019-05-31 | 陶氏环球技术有限责任公司 | 用于施加到粘膜的包含甲基纤维素的组合物 |
| JP2016533172A (ja) | 2013-10-03 | 2016-10-27 | タケダ ワクチン，インコーポレイテッド | 細胞株からラブドウイルスを検出および除去する方法 |
| WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
| AU2016317661B2 (en) | 2015-08-28 | 2023-05-18 | Ology Bioservices, Inc. | Norovirus vaccine |
| KR101915740B1 (ko) * | 2016-03-18 | 2018-11-06 | (주)인테라 | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 |
| CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
| US11833198B2 (en) | 2017-03-28 | 2023-12-05 | Children's Hospital Medical Center | Norovirus S particle based vaccines and methods of making and using same |
| WO2019104439A1 (en) | 2017-11-30 | 2019-06-06 | Medicago Inc. | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| JP2021514391A (ja) | 2018-02-15 | 2021-06-10 | アイコン ジェネティクス ゲーエムベーハー | ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン |
| JP6713013B2 (ja) * | 2018-03-06 | 2020-06-24 | 株式会社イーダブルニュートリション・ジャパン | 貝類のノロウイルス不活化方法 |
| EP3821014A4 (en) | 2018-07-13 | 2022-04-20 | Medicago Inc. | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS WITH MODIFIED NOROVIRUS VP1 PROTEINS |
| JP2021534074A (ja) | 2018-08-20 | 2021-12-09 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | Ｖｌｐ製剤 |
| EP3852820B1 (en) * | 2018-09-17 | 2024-11-20 | Board of Regents, The University of Texas System | Compositions and methods for treating bone injury |
| US11523988B2 (en) * | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
| EP3698773A1 (en) | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
| US20220152186A1 (en) | 2019-03-12 | 2022-05-19 | Icon Genetics Gmbh | Norovirus-like particles with improved stability |
| EP4021409A2 (en) * | 2019-08-13 | 2022-07-06 | Altimmune Inc | Therapeutic agent effectiveness and its route of administration |
| US20240288407A1 (en) * | 2020-06-15 | 2024-08-29 | CureVac SE | Analysis of nucleic acid mixtures |
| WO2022246323A1 (en) | 2021-05-21 | 2022-11-24 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| CN115677838A (zh) * | 2021-07-29 | 2023-02-03 | 成都康华生物制品股份有限公司 | 六价诺如病毒VLPs疫苗及其制备方法 |
| WO2023176206A1 (ja) | 2022-03-18 | 2023-09-21 | デンカ株式会社 | リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子 |
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
| CN117330750A (zh) * | 2023-12-01 | 2024-01-02 | 北京生物制品研究所有限责任公司 | 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU1893592A (en) * | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
| AU683211B2 (en) | 1992-04-08 | 1997-11-06 | United States of America as represented by The Secretary Department of Health and Human Services, The | Wild-type measles virus glycoproteins: vaccine and detection method therefor |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| ES2264126T3 (es) | 1994-05-16 | 2006-12-16 | MERCK & CO., INC. | Vacunas contra el papilomavirus. |
| US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| WO1998044944A2 (en) | 1997-04-08 | 1998-10-15 | Merck & Co., Inc. | Stabilized human papillomavirus formulations |
| AU750702B2 (en) | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| EP1105466B1 (en) | 1998-08-14 | 2006-04-26 | Merck & Co., Inc. | Process for purifying human papillomavirus virus-like particles |
| CA2354444A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
| ATE413188T1 (de) | 1999-02-05 | 2008-11-15 | Merck & Co Inc | Menschliche papillomavirus impfstoff- formulierungen |
| CA2375337C (en) | 1999-06-22 | 2012-09-25 | Naokazu Takeda | Srsv detection kit |
| WO2003068804A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Novel insect cell line |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| JP2006507800A (ja) | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| ATE489969T1 (de) | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| CA2514667C (en) | 2003-01-30 | 2013-01-08 | Chiron Corporation | Adjuvanted influenza vaccine |
| WO2004073652A2 (en) | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US7879338B2 (en) * | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| JP2007537137A (ja) | 2003-09-24 | 2007-12-20 | モンタナ ステート ユニバーシティ | ノロウィルスモノクローナル抗体及びペプチド |
| WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| SG156666A1 (en) | 2004-10-20 | 2009-11-26 | Acambis Inc | Vaccines against japanese encephalitis virus and west nile virus |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| WO2006074303A2 (en) | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
| US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| ES2424229T3 (es) | 2005-03-18 | 2013-09-30 | Cytos Biotechnology Ag | Proteínas de fusión de alérgenos de gato y utilización de las mismas |
| CA2608515A1 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technolgies Inc. | Production of multivalent virus like particles |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| EP2601969B1 (en) * | 2006-09-29 | 2016-03-30 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| CA2683977C (en) | 2007-03-14 | 2017-04-25 | Ligocyte Pharmaceuticals, Inc. | A method of norovirus virus-like particle purification comprising ion exchange chromatography |
| US8474614B2 (en) * | 2007-03-14 | 2013-07-02 | BBY Solutions | Protective container for a flat screen monitor |
| CN104740624B (zh) * | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| JP5852883B2 (ja) | 2008-08-08 | 2016-02-03 | タケダ ワクチン，インコーポレイテッド | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| CA2750321A1 (en) | 2009-01-22 | 2010-07-29 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
| WO2010092476A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| JP2013517773A (ja) | 2010-01-21 | 2013-05-20 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| PH12014500093A1 (en) | 2011-07-11 | 2014-03-17 | Takeda Vaccines Inc | Parenteral norovirus vaccine formulations |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
-
2007
- 2007-09-28 EP EP13157572.2A patent/EP2601969B1/en active Active
- 2007-09-28 EP EP13157573.0A patent/EP2601970B1/en not_active Revoked
- 2007-09-28 EP EP07853688.5A patent/EP2066354B1/en active Active
- 2007-09-28 KR KR1020097008725A patent/KR101515489B1/ko active Active
- 2007-09-28 HU HUE13157573A patent/HUE032422T2/en unknown
- 2007-09-28 DK DK13157573.0T patent/DK2601970T3/en active
- 2007-09-28 LT LTEP13157573.0T patent/LT2601970T/lt unknown
- 2007-09-28 HU HUE13157572A patent/HUE028978T2/en unknown
- 2007-09-28 SI SI200731885A patent/SI2601970T1/sl unknown
- 2007-09-28 DK DK13157572.2T patent/DK2601969T3/en active
- 2007-09-28 ES ES13157573.0T patent/ES2618885T3/es active Active
- 2007-09-28 ES ES07853688T patent/ES2420136T3/es active Active
- 2007-09-28 ES ES13157572.2T patent/ES2577833T3/es active Active
- 2007-09-28 PL PL13157573T patent/PL2601970T3/pl unknown
- 2007-09-28 US US12/093,921 patent/US7955603B2/en active Active
- 2007-09-28 WO PCT/US2007/079929 patent/WO2008042789A1/en not_active Ceased
- 2007-09-28 AU AU2007303608A patent/AU2007303608B2/en not_active Ceased
- 2007-09-28 SG SG10202012986SA patent/SG10202012986SA/en unknown
- 2007-09-28 PL PL13157572.2T patent/PL2601969T3/pl unknown
- 2007-09-28 JP JP2009530639A patent/JP5476544B2/ja active Active
- 2007-09-28 PT PT131575730T patent/PT2601970T/pt unknown
- 2007-09-28 CA CA2664157A patent/CA2664157C/en active Active
- 2007-09-28 SG SG2011071123A patent/SG174845A1/en unknown
- 2007-09-28 EP EP13173005.3A patent/EP2641613A1/en not_active Withdrawn
- 2007-09-28 DK DK07853688.5T patent/DK2066354T3/da active
- 2007-09-28 SG SG10201502490YA patent/SG10201502490YA/en unknown
-
2010
- 2010-06-16 US US12/816,495 patent/US8431116B2/en active Active
-
2011
- 2011-12-20 US US13/330,854 patent/US20120093861A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/837,653 patent/US9308249B2/en active Active
- 2013-03-15 US US13/836,446 patent/US10010599B2/en active Active
- 2013-03-15 US US13/837,885 patent/US9272028B2/en active Active
- 2013-06-24 JP JP2013131559A patent/JP5898133B2/ja active Active
-
2015
- 2015-07-10 US US14/796,714 patent/US9861691B2/en active Active
- 2015-10-05 JP JP2015197633A patent/JP6134364B2/ja active Active
-
2017
- 2017-01-25 CY CY20171100109T patent/CY1118492T1/el unknown
-
2018
- 2018-05-31 US US15/994,887 patent/US10512682B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014141528A5 (cg-RX-API-DMAC10.html) | ||
| JP2010539192A5 (cg-RX-API-DMAC10.html) | ||
| JP2011530295A5 (cg-RX-API-DMAC10.html) | ||
| Sulczewski et al. | Nanoparticle vaccines against viral infections | |
| AU2017203501B2 (en) | Vaccine adjuvant composition comprising inulin particles | |
| CN102177233B (zh) | 用于增强交叉反应性的包含复合衣壳氨基酸序列的病毒样颗粒 | |
| Qiao et al. | Potency of a scalable nanoparticulate subunit vaccine | |
| Tomalka et al. | Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses | |
| ES2568018T3 (es) | Composición de vacuna | |
| Negash et al. | Mucosal application of cationic poly (D, L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease | |
| US9566338B2 (en) | Vaccine delivery method | |
| JP2010163453A5 (cg-RX-API-DMAC10.html) | ||
| Renu et al. | Poly (I: C) augments inactivated influenza virus-chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally | |
| JP2017516834A5 (cg-RX-API-DMAC10.html) | ||
| KR20090079912A (ko) | 노로바이러스 백신 제제 | |
| WO2009039229A3 (en) | Method of conferring a protective immune response to norovirus | |
| KR20240054288A (ko) | 면역원성 증강용 조성물 | |
| CN102791286A (zh) | 杯状病毒病毒样颗粒上靶定异源抗原的呈递 | |
| Masimov et al. | Chitosan non-particulate vaccine delivery systems | |
| JP2011515490A5 (cg-RX-API-DMAC10.html) | ||
| Patil et al. | Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration | |
| AU2019404430A1 (en) | Norovirus vaccine formulations and methods | |
| Bi et al. | The combinations chitosan-Pam3CSK4 and chitosan-monophosphoryl lipid A: promising immune-enhancing adjuvants for anticaries vaccine PAc | |
| JP2011504535A5 (cg-RX-API-DMAC10.html) | ||
| JP2012526149A5 (cg-RX-API-DMAC10.html) |